Day One Biopharmaceuticals, INC

Servier Pharmaceuticals has successfully completed its acquisition of Day One Biopharmaceuticals through a tender offer and subsequent merger, with the transaction closing on April 23, 2026.

Servier Pharmaceuticals will acquire Day One Biopharmaceuticals for $21.50 per share in cash, valuing the company at approximately $2.5 billion.

Day One Biopharmaceuticals' OJEMDA received a positive opinion from the European Medicines Agency's CHMP for conditional marketing authorization in relapsed or refractory BRAF-altered pediatric low-grade glioma.

Day One Biopharmaceuticals announced robust Q4 and full-year 2025 financial results, driven by strong OJEMDA sales, and reaffirmed its 2026 revenue guidance and pipeline progress.

Day One Biopharmaceuticals announced preliminary unaudited 2025 OJEMDA net product revenue of $155.4 million, representing 172% year-over-year growth, and projected 2026 revenue of $225-$250 million.

Day One Biopharmaceuticals successfully acquired Mersana Therapeutics, adding clinical-stage antibody drug conjugate Emi-Le and expanding its oncology pipeline.

Day One Biopharmaceuticals reports significant product revenue growth for OJEMDA in Q3 2025, alongside increased net losses and strategic program adjustments.

Day One Biopharmaceuticals reports significant revenue growth driven by OJEMDA sales, alongside strategic pipeline adjustments and a strong cash position.

Day One Biopharmaceuticals reports a net product revenue of $30.5 million from OJEMDA sales in the first quarter of 2025, alongside a net loss of $36.0 million.

Day One Biopharmaceuticals reports a strong third quarter, marked by the commercial launch of OJEMDA and a significant licensing agreement with Ipsen, resulting in substantial revenue growth.

Day One Biopharmaceuticals reports second quarter 2024 results, including initial OJEMDA sales and a significant licensing agreement with Ipsen for ex-US commercialization.

Day One Biopharmaceuticals announced its first quarter 2024 results, including a net loss of $62.4 million, and highlighted the FDA approval of OJEMDA for pediatric low-grade glioma.

Day One Biopharmaceuticals filed an amendment to its 2025 Annual Report to include required Part II and Part III disclosures and updated Sarbanes-Oxley certifications.

Day One Biopharmaceuticals reports significant revenue growth from its newly approved pediatric brain tumor therapy, OJEMDA, while strategically expanding its oncology pipeline through key acquisitions and licensing deals.

Day One Biopharmaceuticals files an amendment to its 2024 annual report to correct errors in the independent accounting firm's consent and references within the audit reports.

Day One Biopharmaceuticals announces its 2024 financial results, emphasizing the commercial launch of OJEMDA and a strategic licensing agreement with Ipsen.

Day One Biopharmaceuticals is advancing its pipeline with a focus on pediatric cancer, highlighted by positive Phase 2 data for tovorafenib and ongoing Phase 3 trial.

AI Day1 LLC and affiliated entities have disposed of their entire stake in Day One Biopharmaceuticals following a successful tender offer and merger.

Day One Biopharmaceuticals has been acquired by Servier Pharmaceuticals in an all-cash transaction at $21.50 per share.

Michael Vasconcelle reports the disposal of all equity holdings following the completion of Day One Biopharmaceuticals' acquisition by Servier Pharmaceuticals.

Day One Biopharmaceuticals has been acquired by Servier Pharmaceuticals for $21.50 per share in an all-cash transaction.

Day One Biopharmaceuticals has been acquired by Servier Pharmaceuticals for $21.50 per share in an all-cash transaction.

Director Natalie C. Holles reports the disposal of all equity holdings following the completion of Day One Biopharmaceuticals' acquisition by Servier Pharmaceuticals.

Day One Biopharmaceuticals, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) pursuant to Section 14(a) of the Securities Exchange Act of 1934.

Day One Biopharmaceuticals will hold its 2025 Annual Meeting of Stockholders virtually on June 2, 2025, to elect directors, ratify the appointment of its accounting firm, and vote on executive compensation.

Day One Biopharmaceuticals, Inc. has filed a proxy statement with the Securities and Exchange Commission (SEC) pursuant to Section 14(a) of the Securities Exchange Act of 1934.

Day One Biopharmaceuticals will hold its 2024 Annual Meeting of Stockholders virtually on May 23, 2024, to vote on director elections, auditor ratification, executive compensation, and the frequency of future executive compensation votes.

Reporting persons have ceased all beneficial ownership in Day One Biopharmaceuticals following the completion of a tender offer.

AI Day1 LLC has tendered all its shares of Day One Biopharmaceuticals common stock in response to Servier Detroit Inc.'s tender offer.

Vestal Point Capital, LP and Ryan Wilder have filed an amendment reporting a 0% beneficial ownership stake in Day One Biopharmaceuticals, Inc.

Atlas Venture Fund XI, L.P. and related entities have filed a Schedule 13G, reporting 0% beneficial ownership of Day One Biopharmaceuticals, Inc. common stock as of March 31, 2026.

FMR LLC and Abigail P. Johnson have filed a Schedule 13G, reporting beneficial ownership of 23,639.69 shares of Day One Biopharmaceuticals common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Day One Biopharmaceuticals Inc. following an internal realignment.

Glazer Capital, LLC and Paul J. Glazer have reported a 5.4% beneficial ownership stake in Day One Biopharmaceuticals, Inc.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 5.6% beneficial ownership stake in Day One Biopharmaceuticals Inc. as of December 31, 2025.